Cancer Research Annual Meeting 2010  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikegami, T.
Right arrow Articles by Bouscarel, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikegami, T.
Right arrow Articles by Bouscarel, B.
[Cancer Research 62, 179-187, January 1, 2002]
© 2002 American Association for Cancer Research


Experimental Therapeutics

Intestinal Alkalization As a Possible Preventive Mechanism in Irinotecan (CPT-11)-induced Diarrhea1

Tadashi Ikegami, Linan Ha, Kazuhiko Arimori, Patricia Latham, Kunihiko Kobayashi, Susan Ceryak, Yasushi Matsuzaki and Bernard Bouscarel2

Departments of Medicine [T. I., P. L., B. B.], Pharmacology [L. H., S. C.], Pathology [P. L.], and Biochemistry and Molecular Biology [B. B.], The George Washington University Medical Center, N. W. Washington, D.C. 20037; Department of Pharmacy, Miyazaki Medical College, Miyazaki, Japan 889-1692 [K. A.]; Saitama Cancer Center, Saitama, Japan 336-0011 [K. K.]; and Institute of Clinical Medicine, University of Tsukuba, Tsukuba-City, Japan 305-0024 [Y. M.]

The therapeutic efficacy of irinotecan (CPT-11), a DNA topoisomerase inhibitor, is often limited by the induction of severe late-onset diarrhea. This prodrug and its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), have a labile {alpha}-hydroxy-lactone ring that undergoes pH-dependent reversible hydrolysis. At physiological pH and higher, equilibrium favors the less toxic carboxylate form, whereas at acidic pH, the more potent lactone form is favored. We have reported previously that the initial uptake rate of CPT-11 and SN-38 by intestinal cells was significantly different between the respective lactone and carboxylate form. Results from the present study in HT-29 cells further demonstrate the correlation between the CPT-11/SN-38 initial uptake rate and the induced toxicity, cell cycle alteration, apoptosis, and colony-forming efficiency. The exposure of HT-29 cells to SN-38 for a limited period of time (<2 h) was sufficient to induce these events. Because the decreased initial uptake of SN-38 carboxylate resulted in a reduced cellular toxicity, we postulated that the CPT-11-induced diarrhea was preventable by influencing the equilibrium toward the carboxylate form and, thus, reducing its intestinal uptake. In the golden Syrian hamster model, p.o. sodium bicarbonate supplementation (5 mg/ml in drinking water) led to alkalization of the intestinal contents. In addition, this alkalization resulted in the reduction of the histopathological damage to the mucosa of the small and large intestine, as well as a 20% reduction of the intestinal SN-38 lactone concentration of animals receiving CPT-11 (20–50 mg/kg x 7 days). Taken together, these results from in vitro and in vivo studies support intestinal alkalization by sodium bicarbonate supplementation as a preventive mechanism against CPT-11-induced diarrhea. In addition, this provides a strong rationale for the usage of this measure as an adjunct to CPT-11 treatment.




This article has been cited by other articles:


Home page
J Oncol Pharm PractHome page
G. Richardson and R. Dobish
Chemotherapy induced diarrhea
Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 181 - 198.
[Abstract] [PDF]


Home page
Clin. Cancer Res.Home page
G. Brandi, J. Dabard, P. Raibaud, M. Di Battista, C. Bridonneau, A. M. Pisi, A. M. M. Labate, M. A. Pantaleo, A. De Vivo, and G. Biasco
Intestinal Microflora and Digestive Toxicity of Irinotecan in Mice
Clin. Cancer Res., February 15, 2006; 12(4): 1299 - 1307.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Ikegami, Y. Matsuzaki, M. Al Rashid, S. Ceryak, Y. Zhang, and B. Bouscarel
Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid
Mol. Cancer Ther., January 1, 2006; 5(1): 68 - 79.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
Y. Xu and M. A. Villalona-Calero
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity
Ann. Onc., December 1, 2002; 13(12): 1841 - 1851.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.